BV is sexually transmissible — treating male partners cuts relapse by 60%

If you have been through three, four, or five rounds of antibiotics for bacterial vaginosis only to have it return within weeks, you will know the particular demoralisation of that cycle. The antibiotics work — temporarily — and then everything is back. The explanation offered is often that this is just how the body works, or that hygiene or soap are the culprit. That framing is now being challenged directly by Australian clinical research.

New research from Monash University and the Melbourne Sexual Health Centre, published in The Lancet Obstetrics, Gynaecology & Women’s Health, has consolidated a reframing that was building in the literature: bacterial vaginosis is sexually transmissible, and treating male partners alongside the woman at the same time reduces BV recurrence by over 60%.

That is a substantial number. For women who have been quietly absorbing the message that repeat infections are their problem to manage alone, this research offers both a structural explanation and a different clinical pathway.

What the research found

The 2025 Monash trial compared outcomes when male partners received a combination of oral and topical antibiotics at the same time as the woman versus the standard approach of treating only the woman. Concurrent partner treatment reduced BV recurrence by more than 60% compared to the control arm.

The research team identified two distinct mechanisms that drive recurrent BV. The first is re-infection: BV-associated bacteria that were cleared from the vagina are reintroduced by a partner whose own bacterial load was never addressed. The second is persistence: bacteria survive the antibiotic course by forming a biofilm — a structured community embedded in a protective matrix on the vaginal epithelium — and re-establish themselves once treatment ends.

These two pathways have meaningfully different clinical implications. Re-infection responds to partner treatment. Bacterial persistence requires a different clinical response: longer antibiotic courses, antibiotic combinations chosen for biofilm penetration, or newer approaches including live biotherapeutics that aim to displace the dysbiotic microbiome rather than simply suppress it. Identifying which pathway is dominant in a given patient’s history — rather than reflexively re-prescribing the same short course — is the clinical shift this research is driving.

Why this matters beyond the microbiology

BV is the most common vaginal condition in women of reproductive age. It is not currently classified as a sexually transmissible infection under Australian surveillance frameworks, which means it does not come with the partner-notification infrastructure that surrounds gonorrhoea or chlamydia. This classification gap has contributed to a clinical culture where treatment is directed solely at the woman, and re-infection from an untreated partner goes unaddressed and unnamed.

Dr Sara Whitburn, RACGP Chair of General Practice Women’s Health, has described the impact directly: BV “can really impact their self-esteem, it impacts their sexual life, their relationship life.” That is a clinical burden that has been systematically underweighted in the treatment conversation. When a woman presents for the fourth time in a year with recurrent BV, the consult should not be a repeat prescription with a brief note about pH wash. It should include a structured history of the recurrence pattern, a direct conversation about whether her partner has been treated, and a realistic discussion of what the evidence now offers.

Both-and: the antimicrobial stewardship tension

This is the genuine complexity in the research. Partner treatment for BV means prescribing antibiotics — typically a combination of oral azithromycin and topical metronidazole-based therapy — to a person who has no symptoms himself. Against the backdrop of antimicrobial stewardship priorities in Australian general practice, prescribing treatment to an asymptomatic male partner for a condition that does not directly harm him requires a considered conversation rather than a reflexive script.

The Monash researchers acknowledge this tension explicitly. The case for partner treatment is not that it should be universal or automatic. It is that for women with documented recurrent BV — particularly those who have already failed multiple treatment courses — the stewardship calculus shifts when placed against the accumulated exposure of repeated antibiotic courses in the woman, the ongoing quality-of-life toll, and a recurrence rate that the woman-only model is demonstrably failing to address.

Biofilm-disrupting agents and live biotherapeutics represent the emerging next chapter of BV management, with lower antibiotic burden. These remain in the trial pipeline. Current general practice is working with the evidence available now — and that evidence supports concurrent partner treatment for recurrent cases.

2 cents

If recurrent BV is something you have been managing with repeat prescriptions that keep not working, it is worth going back to your GP with a specific question: has partner treatment been considered, and does the pattern fit re-infection or persistence? These are now answerable clinical questions, not unanswerable mysteries.

The upcoming published findings from the Monash group are expected to further refine the clinical algorithm. The 60% recurrence reduction from concurrent partner treatment is already a number that supports changing the default approach in the consult.

Verdict: yes — worth knowing about.

---

Sources cited

1. Researchers pursue lasting cure for recurrent BV — newsGP, RACGP